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Abstract
Background:  Catechol-O-methyltransferase (COMT), an enzyme that metabolizes
catecholamines, has recently been implicated in the modulation of pain. Specifically, low COMT
activity is associated with heightened pain perception and development of musculoskeletal pain in
humans as well as increased experimental pain sensitivity in rodents.
Results:  We report that the proinflammatory cytokine tumor necrosis factor α (TNFα)
downregulates COMT mRNA and protein in astrocytes. Examination of the distal COMT promoter
(P2-COMT) reveals a putative binding site for nuclear factor κB (NF-κB), the pivotal regulator of
inflammation and the target of TNFα. Cell culture assays and functional deletion analyses of the
cloned P2-COMT promoter demonstrate that TNFα inhibits P2-COMT activity in astrocytes by
inducing NF-κB complex recruitment to the specific κB binding site.
Conclusion: Collectively, our findings provide the first evidence for NF-κB-mediated inhibition of
COMT expression in the central nervous system, suggesting that COMT contributes to the
pathogenesis of inflammatory pain states.
Background
Catechol-O-methyltransferase (COMT) metabolizes cate-
cholamines and thereby acts as a key modulator of
dopaminergic and adrenergic/noradrenergic neurotrans-
mission [1,2]. Converging lines of evidence have revealed
an important role of COMT in the etiology and pathogen-
esis of a wide variety of central nervous system (CNS) dis-
orders [2-4]. Recently, COMT has also been implicated in
the regulation of pain perception [5,6]. Myofacial pain
patients exhibit lower COMT activity relative to controls
[7], and COMT inhibition increases pain sensitivity in
rodents by promoting catecholamine stimulation of β2-
and β3-adrenergic receptors [8].
The COMT protein exists in two major forms: a shorter
soluble form (S-COMT) and a longer membrane-bound
form (MB-COMT). They are encoded from one gene by
two mRNA transcripts (1.3 and 1.5 kb in human, 1.6 and
1.9 kb in rats) regulated by the proximal P1 and distal P2
promoters, respectively [9-11]. Only the longer transcript
was found in the brain [12] with the predominant protein
being MB-COMT. However, S-COMT protein is also
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expressed in the brain from the longer MB-COMT mRNA
isoform via  a leaky scanning mechanism [13]. Though
their sequences are largely homologous, MB-COMT has
approximately a 10-fold greater affinity for dopamine and
noradrenaline relative to S-COMT [14]. Seven novel
COMT mRNA variants have also been detected in brain,
however, they likely to exist at much lower levels than the
primary transcript [15]. Although recent reports describe a
neuronal expression of COMT [16], it is primarily consid-
ered a glial enzyme [17-19].
A significant role for glia in mediating pain has been
implicated by studies of patients with persistent pain con-
ditions and animal models of pain [20-22]. Proinflamma-
tory cytokines are produced and released by activated
microglia and astrocytes in the CNS as well as by immune
cells at the site of injury or inflammation. [23-26]. TNFα
is widely considered to be the prototypic proinflamma-
tory cytokine due to its principal role in initiating the cas-
cade of cytokines and growth factors involved in the
inflammatory response [20]. Tissue levels of TNFα have
been correlated with pain report in a number of painful
diseases [27-29]. TNFα activates NF-κB, which is the piv-
otal regulator of cellular inflammatory responses [30-32].
Specifically, the NF-κB pathway plays one of the major
roles in injury or inflammation-evoked activation of
astrocytes [23,33,34]. Within the nervous system, NF-κB
is most frequently composed of two DNA-binding subu-
nits (p65/Rel A and p50) that form a complex with the
inhibitory subunit IκB which normally retains NF-κB
within the cytoplasm of unstimulated cells [35]. Signal-
induced phosphorylation, ubiquitination, and degrada-
tion of IκB triggers NF-κB nuclear translocation and DNA
binding. Phosphorylation of IκB is mediated by the IκB
kinase (IKK) complex, which consists of two catalytic sub-
units, IKKα and IKKβ, and the regulatory subunit IKKγ
[36]. Gene knock-out studies have established an essential
role for IKKβ in TNFα-induced activation of NF-κB [37].
A growing number of reports reveal a crucial role of NF-κB
in nociception. NF-κB activity is increased in animal mod-
els of neuropathic and inflammatory pain [38-42]. A spe-
cific IKK inhibitor reverses heightened pain sensitivity to
noxious (hyperalgesia) and normally innocuous stimuli
(allodynia) [43]. Increased neuropathic and inflamma-
tory pain is suppressed by pretreatment with an NF-κB
inhibitor [39,44]. Interestingly, selective inactivation of
NF-κB in glial cells or astrocytes leads to decreased pain
and better functional recovery [45-47].
Despite increasing evidence for an important role of NF-
κB in pain regulation, very few studies have addressed the
mechanisms whereby this pathway exerts its effects on
nociception [38,39,41,43,48]. We hypothesized that NF-
κB regulates expression of COMT, an enzyme known to
contribute to enhanced pain states. Thus, the present
study explored the relationship between the NF-κB path-
way and COMT expression in order to gain an under-
standing of the cellular mechanisms underlying
inflammatory pain.
Results
TNF  inhibits endogenous COMT expression in astrocytes
To elucidate a potential role of TNFα in regulating COMT
expression, we treated rat primary astrocytes with TNFα
and measured COMT protein levels using Western blot
analysis. A significant reduction in COMT protein expres-
sion was observed beginning at 8 h (Figure 1A) with a
60% maximal decrease relative to untreated control (P <
0.05; Figure 1B). Using quantitative real-time RT-PCR
analysis, we further demonstrated a down-regulation of
MB-COMT mRNA at 0.5 h and 30 h following TNFα treat-
ment (P < 0.01; Figure 1C). This oscillatory rather than
linear pattern of MB-COMT mRNA expression is in agree-
ment with previously reported characteristics of NF-kB-
mediated gene regulation and has been associated with
autoregulation of NF-κB activity, as one of the genes acti-
vated by NF-κB is that encoding its own inhibitor, IκBα
[49]. Finally, a dye exclusion test verified that the TNFα-
dependent down-regulation of COMT was not due to
cytotoxic effects as more than 95% of cells treated with
TNFα remained viable (data not shown).
Cloning and structural analysis of the human distal COMT 
promoter
To study the signaling mechanisms whereby TNFα regu-
lates COMT expression, we cloned the human distal
COMT  promoter (P2-COMT)  which controls transcrip-
tion of MB-COMT mRNA (Figure 2A). A 1.5 kb DNA frag-
ment corresponding to the previously published P2-
COMT  sequences [GenBank: Z26490 and AF001102]
[11,50] was cloned in the pGL3 luciferase reporter vector.
Using TFSearch database [51], we analyzed the cloned
sequence and identified a number of potential transcrip-
tion factor binding elements that can affect both constitu-
tive and tissue-specific expression of COMT gene, such as
TATA and CAAT boxes, CRE, C/EBP, and NF-κB sites. The
presence of the NF-κB consensus binding site 5'-
GGGGACGCCC-3' at position -109 from the first tran-
scription initiation site of MB-COMT indicated that this
promoter could be regulated by NF-κB pathway and
respond to TNFα treatment.
COMT inhibition by TNF  requires NF- B activation
Luciferase reporter gene assays were employed to test the
effect of TNFα treatment on P2-COMT activity. A chimeric
human  P2-COMT/Luc  construct was transiently trans-
fected into human H4 astroglioma cells. Consistent with
the observed down-regulation of endogenous COMT
expression, TNFα treatment decreased P2-COMT activityMolecular Pain 2009, 5:13 http://www.molecularpain.com/content/5/1/13
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in time-dependent manner. After a 24-hour incubation
with TNFα, P2-COMT activity was reduced to 60% relative
to untreated control (P < 0.05 and P < 0.001 at 16 h and
24 h, respectively; Figure 2B). To test if the TNFα-medi-
ated inhibition of P2-COMT activity requires NF-κB path-
way activation, H4 astroglial cells stably transfected with
IκBα super-repressor (SR), a nondegradable dominant-
negative inhibitor of all NF-κB complexes, were tran-
siently transfected with P2-COMT/Luc construct and P2-
COMT activity was measured during 24 h of TNFα treat-
ment. H4 IκBα-SR cells were no longer sensitive to TNFα-
mediated inhibition of P2-COMT activity (Figure 2B).
As NF-κB is generally recognized as a positive regulator of
gene expression, we used a reporter vector with a pro-
moter known to be up-regulated in response to NF-κB
activation. A luciferase reporter vector containing κB con-
sensus sites from the MHC class I promoter was trans-
fected into H4 astroglioma cells. After treatment with
TNFα, the MHC promoter reporter showed a 14-fold
increase in expression, demonstrating that the TNFα-
mediated inhibition of COMT expression in astroglioma
cells is P2-COMT promoter specific (P < 0.05; Figure 2C).
Finally, to test effect of NF-κB pathway on endogenous
COMT expression, we also treated H4 IκBα-SR cells with
TNFα. Consistent with reporter assay results, TNFα was
unable to significantly repress endogenous COMT protein
and mRNA levels in H4 IκBα-SR cells (P > 0.05 for protein
level and P > 0.05 for mRNA; Figure 3A, B, and 3C).
TNF  inhibits COMT via a canonical NF- B activation 
mechanism
As TNFα may function via NF-κB and JUN N-terminal
kinase (JNK) signaling cascades [52], we sought to deter-
mine whether a signal that elicits NF-κB activation alone
would repress COMT gene expression. Thus, we tested if
overexpression of p65 or IKKβ, which are both essential
for NF-κB activation, would negatively regulate P2-COMT
activity. Our data demonstrate that p65 or IKKβ overex-
pression dramatically decreases P2-COMT  activity (P  <
0.01; Figure 4A).
Next, we examined whether TNFα engaged the canonical
mechanism of IκBα phosphorylation and degradation to
trigger transport of NF-κB to the nucleus in our experi-
mental conditions. H4 cells were treated with TNFα and
then cytoplasmic and nuclear extracts analyzed by West-
ern blot. The degradation of IκBα in the cytoplasmic frac-
tion of the cells and simultaneous increase in the nuclear
level of p65 was observed at 30 min (Figure 4B and 4C),
characteristic of dynamic NF-κB signaling [53]. Together,
these results demonstrate that TNFα initiates the canoni-
cal IκBα degradation pathway to activate NF-κB in H4
astroglioma cells, and that NF-κB activation inhibits
COMT in glial cells.
Identification of the functional NF- B binding site in the 
P2-COMT promoter
To identify the NF-κB-responsive region in the P2-COMT
promoter, we analyzed the activity of serial 5'deletions of
the P2-COMT/Luc constructs transiently transfected into
H4 or H4 IκBα-SR cells (Fig. 5A). Consequent deletions of
COMT expression is downregulated by TNFα in primary  astrocytes Figure 1
COMT expression is downregulated by TNFα in pri-
mary astrocytes. Administration of TNFα (20 ng/ml) 
decreases COMT protein expression in primary astrocytes 
as indicated by (A) a representative Western blot and (B) 
quantitative analysis of Western blots from experiments per-
formed in triplicate. (C) Administration of TNFα (20 ng/ml) 
also decreases MB-COMT mRNA expression in primary 
astrocytes. Data are Means ± SEM. *P < 0.05 and **P < 0.01 
different from untreated control.
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5'fragments led to a graduate increase in overall basal pro-
moter activity in all constructs, suggesting the presence of
serial putative negatively regulating elements along the
P2-COMT promoter. Del.2 construct that lack the putative
κB consensus binding site also showed a lack of response
to TNFα treatment in either H4 or H4 IκBα-SR cells (P >
0.05; Figure 5B and 5C). Conversely, TNFα treatment of
H4 but not H4 IκBα-SR cells inhibited activity of construct
Del.1 containing the putative κB consensus binding site
and the initial P2-COMT promoter construct (P < 0.05 for
H4 cells and P > 0.05 for H4 IκBα-SR cells; Figure 5B and
5C). Thus, the region between position -155 and -33
appears to be crucial for TNFα-dependent suppression of
P2-COMT activity.
To determine whether TNFα induces NF-κB binding to
the consensus DNA site of the identified region, we used
ELISA to detect bound NF-κB p65 subunits. This method
was employed as an alternative to the electrophoretic
mobility shift assay, as it was reported to be more sensitive
and quantitative [54]. DNA binding of p65 was dramati-
cally increased in nuclear extracts of H4 cells after 30 min
of TNFα treatment (P < 0.001; Figure 5D). This binding
was abrogated by incubation of the nuclear extracts with
either a competing control wild-type κB consensus oligo-
nucleotide (Figure 5D, WT BC oligo) or with a competing
oligonucleotide containing a wild-type putative κB bind-
ing sequence 5'-GGGGACGCCC-3' at position -109 in the
P2-COMT  promoter (Figure 5D, WT P2 oligo). Con-
versely, both oligonucleotides containing either a
mutated version of the control κB consensus sequence
(Figure 5D, MT BC oligo) or a mutated sequence 5'-GCT-
CACGCCC-3' of the putative κB binding site of the P2-
COMT promoter (Figure 5D, MT P2 oligo) had a minimal
Activity of P2-COMT promoter is downregulated by TNFα in H4 astroglial cells Figure 2
Activity of P2-COMT promoter is downregulated by TNFα in H4 astroglial cells. (A) Schematic diagram of human 
COMT gene. The exon-intron organization is not to scale. The positions of translation start codons for MB-COMT (MB-ATG) 
and S-COMT (S-ATG) polypeptides, translation stop codon (TGA), putative polyadenylation signal (AATTAA), promoter 
regions, and primers (U1 and D1) are shown. (B) Administration of TNFα (20 ng/ml) inhibits activity of transfected P2-COMT/
Luc reporter in H4 but not in H4 IκBα-SR cells. Data are Means ± SEM. *P < 0.05, ***P < 0.001 H4 different from H4 IκBα-SR 
cells at 16 and 24 h, respectively. (C) TNFα-mediated inhibition is specific to P2-COMT promoter. The activity of 3x- B/Luc 
reporter (κB consensus sites from the MHC class I promoter) was tested after treatment with TNFα (20 ng/ml) for 24 h. *P < 
0.05 different from untreated control.
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effect on TNFα-induced p65 binding. Results from these
experiments confirm that TNFα induces p65 recruitment
to the functional κB binding site at position -109 in the
P2-COMT promoter.
Discussion
In the present report, we provide the first demonstration
that COMT gene expression is downregulated by TNFα in
primary rat astrocytes at both protein and mRNA levels. As
the  P2-COMT  promoter controls expression of MB-
COMT, the main COMT transcript in brain, this promoter
was cloned from human genomic DNA and transfected in
H4 astroglioma cells. The activity of the cloned promoter
was substantially suppressed by TNFα in a time-depend-
ent manner.
A number of putative regulatory elements have been
described in P1- and P2-COMT  promoters, including
estrogen response (ER) elements [50] that likely mediate
estradiol-dependent downregulation of COMT expression
in cell culture [55]. P2-COMT  also contains abundant
methylation sites associated with cancer development
[56], schizophrenia, and bipolar disorder [57]. We identi-
fied a novel putative regulatory site – a κB consensus
sequence that is a potential target for TNFα-dependent
NF-κB activation.
Next, we demonstrated that TNFα-dependent COMT
downregulation was indeed mediated by the NF-κB path-
way. Transient expression of p65, the essential compo-
nent of NF-κB complexes, or IKKβ, the major positive
regulator of NF-κB activition, significantly decreased P2-
COMT reporter expression. In addition, H4 IκBα-SR cells
lost the ability to regulate P2-COMT promoter expression
in response to TNFα treatment. The TNFα-mediated sup-
pression of endogenous COMT expression was also abro-
gated in H4 IκBα-SR cells. Moreover, we confirmed that
TNFα activated NF-κB in H4 astroglioma cells through the
canonical IκB degradation pathway to trigger p65 nuclear
translocation and DNA binding.
Our data strongly suggest that the putative κB binding site
5'-GGGGACGCCC-3' at position -109 of the P2-COMT
promoter region is a functional site for NF-κB-mediated
regulation of COMT expression as deletion of the P2-
COMT  region containing this site abrogated TNFα-
dependent inhibition of P2-COMT activity in H4 astrogli-
oma cells. Furthermore, competition experiments per-
formed with the wild type or mutant site-specific
oligonucleotides showed that TNFα indeed induced
recruitment of p65 to this κB consensus binding site of the
promoter.
Although NF-κB-mediated activation of transcription is
well known, the mechanisms of NF-κB-mediated repres-
sion are poorly established. Probably, the best studied
example of transcriptional repression by NF-κB complex
is described for Dorsal transcription factor, a Drosophila
Rel family member that can either activate or repress gene
expression through the recruitment of coactivators such as
CBP or corepressors such as Groucho [58]. Furthermore, a
number of examples have been reported in mammals. NF-
κB can repress transcription by competing with steroid
receptors for a common promoter cis-DNA element
TNFα-mediated repression of COMT is attenuated in H4  IκBα-SR astroglial cells Figure 3
TNFα-mediated repression of COMT is attenuated 
in H4 IκBα-SR astroglial cells. Administration of TNFα 
(100 ng/ml) does not reduce COMT expression in H4 IκBα-
SR cells as indicated by (A) a representative Western blot, 
(B) quantitative analysis of Western blots from experiments 
performed in triplicate, and (C) quantitative real-time RT-
PCR analysis of MB-COMT mRNA. P > 0.05 different from 
untreated control.
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[59]via N-myc recruitment to the glutamate transporter
gene promoter [53] and through inhibiting histone H4
acetylation at the cytochrome P-450 1A1 promoter [60].
Thus, further experiments should be conducted to address
the specific mechanism underlying NF-κB-dependent
inhibition of COMT gene expression. Interestingly, conse-
quent deletions of 5'fragments of the P2-COMT promoter
led to a significant increase in overall basal promoter
activity. This result would suggest the presence of a
number of putative negatively regulating elements along
the P2-COMT promoter other than ER- and κB-response
elements. Although, to date, no studies have systemati-
cally searched for regulators of COMT expression, this
finding clearly warrants further research.
Our results demonstrating that COMT expression is
downregulated in astrocytes under inflammatory condi-
tions are in line with those of other studies showing a pos-
itive correlation between astrocyte activation and
exaggerated pain responses [24,25,61]. Intrathecal injec-
tion of gp120 (human immunodeficiency virus-1 enve-
lope glycoprotein) induces mechanical allodynia via the
release of proinflammatory cytokines and NF-κB activa-
tion in spinal cord astrocytes, but not in microglial cells or
neurons [62]. Selective inactivation of astroglial NF-κB in
transgenic mice expressing a dominant negative form of
the inhibitor IκBα leads to a dramatic improvement in
functional recovery after contusive spinal cord injury
(SCI) [46] and decreases formalin-induced pain [47].
Additionally, several recent studies report cell type-spe-
cific NF-κB activation by cytokines. For example, in rat
brain cultures IL-1 induces NF-κB activation in astrocytes,
but not in neurons [63,64]. Taken together, these studies
unequivocally link NF-κB activation in astrocytes to pain
states.
Although activation of the NF-κB pathway has been
deemed critical for the development of pain [40-42], there
are few reports studying NF-kB-dependent pro-nocicep-
tive signaling. Historically, these studies have focused on
NF-kB-dependent up-regulation of pro-inflammatory
cytokines [25,65], cyclooxygenase-2 (COX-2) [39,43],
inducible and neuronal nitric oxide synthases (iNOS and
nNOS) [38,41], c-src [48], and c-fos [38]. However, recent
studies from our group demonstrated that genetic variants
of COMT coding for low enzymatic activity are associated
with heightened experimental pain sensitivity and the
onset of a myofacial pain condition in humans [5]. Addi-
tionally, pharmacologic inhibition of COMT in a rat
model of inflammation resulted in elevated pain sensitiv-
ity [8]. Together, these data suggest that an NF-κB-medi-
ated decrease in COMT expression is likely to contribute
to heightened pain sensitivity under inflammatory condi-
tions. A series of in vivo experiments further addressing
this hypothesis are currently being conducted in our labo-
ratory.
Conclusion
Collectively, our results provide the first evidence that
COMT expression is downregulated in astrocytes via
recruitment of the NF-κB complex to a specific κB-site at
the P2-COMT  promoter. NF-κB-mediated inhibition of
COMT in the CNS may represent a novel mechanism con-
tributing to inflammatory pain. NF-κB is regarded as one
of the most important targets for therapeutic intervention
against inflammatory conditions [66,67]; thus, elucidat-
NF-κB is required for COMT downregulation Figure 4
NF-κB is required for COMT downregulation. (A) Cotransfection of pCMV-SPORT-M-p65 or pCMV-SPORT-M-IKKβ 
inhibits P2-COMT/Luc reporter activity in H4 cells. Data are Means ± SEM. **P < 0.01 different from P2-COMT/Luc alone. West-
ern blot analysis was performed with protein extracts from H4 cells treated with TNFα (20 ng/ml) for the indicated time-
points. Expression of IκBα was evaluated in cytoplasmic fraction of H4 cells (B), whereas p65 and p50 protein levels were 
tested in nuclear extracts (C).
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Identification of TNFα-responsive region in the P2-COMT promoter Figure 5
Identification of TNFα-responsive region in the P2-COMT promoter. (A) Schematic diagram of the P2-COMT/Luc con-
struct and its serial deletions Del.1 and Del.2. The effect of TNFα (20 ng/ml, 8 h of treatment) on the relative activity of the P2-
COMT/Luc, Del.1 and Del.2 constructs transfected into H4 (B) and H4 IκBα-SR (C) cells. Data are Means ± SEM. *P < 0.05 dif-
ferent from untreated control. (D) Binding of p65 to a plate-immobilized oligonucleotide containing a κB binding site was meas-
ured by TransAM NF-κB assay in the nuclear extracts from H4 cells 30 min post TNFα treatment. This activation was 
prevented by competition with a wild-type binding control (WT BC) κB consensus oligonucleotide or a wild-type P2-COMT κB 
consensus oligonucleotide (WT P2). Oligonucleotides with mutated κB binding sites – a mutant binding control (MT BC) and a 
mutant P2-COMT (MT P2-COMT) – had little or no effect. Data are Means ± SEM. ###P < 0.001 TNFα-treated different from 
untreated control, ***P < 0.001 TNFα-treated different from TNFα+WT BC and WT P2 oligos, *P < 0.05 TNFα-treated dif-
ferent from TNFα+MT BC oligo.
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ing the cellular mechanisms that underlie NF-κB-medi-
ated inflammatory pain will promote the development of
novel therapies including pharmacologic agents that
block COMT-dependent pain signaling.
Methods
Cell culture and reagents
Primary astrocytes were isolated and cultured as described
earlier [68]. Human H4 astroglioma cells were obtained
from ATCC (HTB-148) and cultured in DMEM (Sigma),
10% fetal bovine serum (FBS; HyClone) and 1× penicil-
lin-streptomycin (Invitrogen). H4 cells stably expressing
IκBα-SR were a generous gift from Dr. Baldwin (UNC)
and generated as described previously [53]. All oligonu-
cleotides were obtained from MWG-Biotech AG. The
pCMV-SPORT-M, pCMV-SPORT-M-p65 and pCMV-
SPORT-M-IKKβ expression vectors were a generous gift
provided by Dr. Romanov (Attagene) and 3x-κB/luc con-
struct was a gift from Dr. Baldwin (UNC).
Quantitative real-time RT-PCR
Total RNA was isolated using the Trizol reagent (Invitro-
gen), treated with RNase free-DNase I (Promega) and
reverse transcribed with random primers by Superscript III
(Invitrogen). The cDNA was amplified with SYBR Green
PCR master mix (Applied Biosystems) using forward and
reverse PCR primers (5'-CCAGAGGAGACCCCAGACC-3'
and 5'-ACAGCTGCCAACAGCAGAG-3', respectively, for
human MB-COMT; 5'-GGAAATCGTGCGTGACATC-3'
and 5'-CATGGATGCCAAGGATTC-3', for human β-actin;
5'-CCAGAGGAGACCCCAGACC and 5'-ACAGCTGCCAA
CAGCAGAG-3', for rat MB-COMT; and 5'-TGCGGGT-
CATAAGCTTGC-3' and 5'-CGATCCGAGGGCCTCACTA-
3' for rat 18S rRNA) in S2 Real Time PCR machine
(Eppendorf). PCR reactions were performed in triplicate.
Three independent experiments were performed, and the
result of a representative experiment is shown. MB-COMT
mRNA levels were normalized to β-actin RNA or 18S
rRNA as an endogenous control.
Western blot analysis
10–50 μg of protein lysates from whole cells, nuclear and
cytoplasmic extracts, normalized for protein content
using a BCA Protein Assay Kit (Pierce), were run on pre-
cast Novex Tris-Glycine gels (Invitrogen), blotted onto
nitrocellose (Whatman), and blocked in TBST with 5%
nonfat dry milk. The following antibodies were used:
COMT (Chemicon, AB5873), β-actin (I-19) (Santa Cruz,
SC-1616), IκBα (C-21) (Santa Cruz, SC-371), p65 (Cell
Signaling, #3034), and p50 (Santa Cruz, SC-7178).
Chemiluminescence was detected in ImageQuant-ECL
Imaging System (GE Healthcare) and images were ana-
lyzed using ImageQuant TL software (GE Healthcare).
Blots from three independent experiments were densito-
metrically analysed and the values normalized to the β-
actin control, with untreated group set to 100%.
Cloning of human P2-COMT distal promoter
Primers  U1  5'-CCTACGCGTGCTCCTCTGGCGGAAAG-
GAA-3' and D1  5'-CGAAGATCTACCTCTCCCGCGACG-
GCCCG-3', with added Mlu I and Bgl II restriction sites,
respectively, were used to amplify P2-COMT from 50 ng
of human genomic DNA with GeneAmp PCR kit (Applied
Biosystems). The 1.5 kb PCR product was digested by Mlu
I and Bgl II restrictases (NEB), gel-purified, ligated into
pGL3 Luciferase Reporter Vector (Promega) using Rapid
DNA Ligation Kit (Roche) and transformed into compe-
tent E. coli DH5α cells (Invitrogen). Recombinant plas-
mids were isolated using EndoFree Plasmid Kit (Qiagen)
and sequenced at UNC sequencing facility. Putative regu-
latory elements were determined with TFSearch database
http://www.cbrc.jp/research/db/TFSEARCH.html.
Construction of serial 5'-end deletions of human P2-
COMT/Luc clone
Serial deletions were generated by PCR amplification of
corresponding fragments from P2-COMT/Luc clone using
forward primers, containing Mlu I restriction site, and
reverse primers, containing Bgl II site, U2  5'-
CCTACGCGTGCGGACACCCTCACGAGGACA-3' and
D1, respectively, for Del. 1, and U3 5'-CCTACGCGTCCAC
CGGAAGCGCCCTCCTA-3' and D1 for Del. 2. The ampli-
fied fragments were digested by Mlu I and Bgl II, purified
from the agarose gel and cloned into pGL3 reporter vec-
tor. Deletions were confirmed by sequencing. The nucle-
otide numeration was based on Tenhunen et al. [11].
Transient transfection, luciferase and  -galactosidase 
assays
Cells were seeded into 12-well plates (5 × 104cells/well)
and transfected with 500 ng of total DNA using FuGene 6
reagent (Roche). Normally, up to 400 ng of P2-COMT
luciferase reporter and 30 ng of control plasmid for trans-
fection efficiency (pSV-β-galactosidase vector, Promega)
were used for transfection. The amount of DNA was kept
constant by addition of pCMV-Sport-M vector with no
insert. Cells were treated by TNFα (R&D Systems) and har-
vested 48 h after transfection. Luciferase activity was deter-
mined using Luciferase Assay System (Promega) and
normalized for transfection efficiency by measuring the β-
galactosidase activity using a β-Galactosidase Enzyme
Assay System (Promega). Transfections were performed in
triplicate, and a representative experiment is shown.
ELISA for activated NF- B
NF-κB activation was measured using TransAM NF-κB
p65 Chemi Kit (Active Motif). Cell lysates were tested for
their ability to bind to a plate-immobilized oligonucle-
otide containing a κB consensus binding site (5'-Molecular Pain 2009, 5:13 http://www.molecularpain.com/content/5/1/13
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GGGACTTTCC-3'). Competition experiments were per-
formed with the wild-type (ACCGCGGGGACGCCCG-
GGGACGCCCCGACC) and mutant (5'-ACCGCGCTC
ACGCCCGCTCACGCCCCGACC) oligonucleotides spe-
cific to P2-COMT κB binding site and κB wild-type and
mutated consensus oligonucleotides provided by the
manufacturer. The wild-type but not mutated oligonucle-
otides were expected to compete with NF-κB for binding.
Chemiluminescence was measured in 1420 Multilabel
Counter Victor3 (PerkinElmer). Nuclear extracts were pre-
pared using Nuclear Extract Kit (Active Motif).
Statistical Analysis
Protein, mRNA, and promoter activity data were analyzed
by paired t-test and analysis of variance (ANOVA) with
post-hoc tests. P < 0.05 was considered to be statistically
significant.
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